IN2014CN03111A - - Google Patents

Download PDF

Info

Publication number
IN2014CN03111A
IN2014CN03111A IN3111CHN2014A IN2014CN03111A IN 2014CN03111 A IN2014CN03111 A IN 2014CN03111A IN 3111CHN2014 A IN3111CHN2014 A IN 3111CHN2014A IN 2014CN03111 A IN2014CN03111 A IN 2014CN03111A
Authority
IN
India
Prior art keywords
enantiomers
fatty acids
well
methods
hydroxy
Prior art date
Application number
Other languages
English (en)
Inventor
Ruiz Pablo Vicente Escribá
Coblijn Gwndolyn Barceló
María Laura Martín
Jiménez Silvia Terés
Salv María Ant Nia Noguera
Xaubet Xavier Busquets
Jiménez David López
Aizpitarte Maitane Ibarguren
Salvador José Javier Soto
Astiz Miguel Yus
Original Assignee
Univ Illes Balears
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illes Balears filed Critical Univ Illes Balears
Publication of IN2014CN03111A publication Critical patent/IN2014CN03111A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42Separation; Purification; Stabilisation; Use of additives
    • C07C51/487Separation; Purification; Stabilisation; Use of additives by treatment giving rise to chemical modification
    • C07C51/493Separation; Purification; Stabilisation; Use of additives by treatment giving rise to chemical modification whereby carboxylic acid esters are formed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/42Unsaturated compounds containing hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IN3111CHN2014 2011-10-07 2012-10-08 IN2014CN03111A (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201131622A ES2401629B1 (es) 2011-10-07 2011-10-07 Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
US201261610762P 2012-03-14 2012-03-14
PCT/ES2012/070697 WO2013050644A1 (es) 2011-10-07 2012-10-08 Enantiómeros de 2-hidroxiderivados de ácidos grasos

Publications (1)

Publication Number Publication Date
IN2014CN03111A true IN2014CN03111A (de) 2015-07-03

Family

ID=48043212

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3111CHN2014 IN2014CN03111A (de) 2011-10-07 2012-10-08

Country Status (12)

Country Link
US (1) US9359281B2 (de)
EP (2) EP3287437B1 (de)
JP (1) JP2014530806A (de)
CN (1) CN104321300A (de)
DK (1) DK2774910T3 (de)
ES (3) ES2401629B1 (de)
HU (1) HUE035430T2 (de)
IN (1) IN2014CN03111A (de)
PL (1) PL2774910T3 (de)
PT (1) PT2774910T (de)
RU (2) RU2687967C2 (de)
WO (1) WO2013050644A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2345241B1 (es) * 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
KR101970151B1 (ko) * 2014-10-21 2019-04-19 유니버시다드 데 레스 일레스 발레아르스 하이드록시-트리글리세라이드의 합성 방법 및 질병의 예방 및 치료에 사용되는 하이드록시-트리글리세라이드의 용도
US11260042B2 (en) * 2017-05-16 2022-03-01 Ability Pharmaceuticals S.L. Pharmaceutical combination for the treatment of cancer
CA3082144A1 (en) 2017-11-16 2019-05-23 The Research Foundation For The State University Of New York Use of 2-hydroxyoleic acid for the treatment of systemic lupus erythematosus and other immune pathologies
ES2911474B2 (es) * 2020-11-17 2023-02-06 Univ Illes Balears Profarmacos de acidos grasos monoinsaturados y sus metabolitos: usos medicos y como biomarcadores
ES2846824B2 (es) * 2020-01-29 2022-01-19 Univ Illes Balears Profarmacos de acidos grasos poliinsaturados y usos medicos de los mismos
CA3166307C (en) * 2020-01-29 2024-05-21 Pablo Vicente Escriba Ruiz Alpha-hydroxylated fatty acid metabolites, medical uses of same and use as biomarkers
BR112022014074A2 (pt) * 2020-02-10 2022-09-13 Ability Pharmaceuticals S L Combinação farmacêutica para o tratamento de um câncer
ES2982396A1 (es) * 2023-03-14 2024-10-15 Veritas Therapeutics S L 2-hidroxi-octadecen-9-cis-oato para uso en el tratamiento de patologias oncologicas y del dolor neuropatico

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2235541C2 (ru) * 1994-10-04 2004-09-10 Эмори Юниверсити Лечение атеросклероза и других сердечно-сосудистых и воспалительных заболеваний
AUPR547601A0 (en) * 2001-06-05 2001-06-28 Carcraft Qld Pty Ltd Tab with writing surface
ES2186576B1 (es) * 2001-10-11 2004-09-16 Universitat De Les Illes Balears Acido 2-hidroxioleico para utilizar como medicamento.
ES2342997B1 (es) * 2008-12-09 2011-06-06 Universitat De Les Illes Balears Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.
ES2345241B1 (es) * 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.

Also Published As

Publication number Publication date
US20140288176A1 (en) 2014-09-25
ES2401629A1 (es) 2013-04-23
JP2014530806A (ja) 2014-11-20
PT2774910T (pt) 2018-01-03
ES2773784T3 (es) 2020-07-14
EP2774910A4 (de) 2015-02-25
ES2653675T3 (es) 2018-02-08
DK2774910T3 (en) 2018-01-08
RU2017141446A3 (de) 2019-02-13
US9359281B2 (en) 2016-06-07
EP3287437B1 (de) 2019-12-11
RU2687967C2 (ru) 2019-05-17
RU2014118123A (ru) 2015-11-20
HUE035430T2 (en) 2018-05-02
RU2637937C2 (ru) 2017-12-08
WO2013050644A1 (es) 2013-04-11
RU2017141446A (ru) 2019-02-13
EP2774910B1 (de) 2017-09-27
ES2401629B1 (es) 2014-03-04
PL2774910T3 (pl) 2018-03-30
EP3287437A1 (de) 2018-02-28
EP2774910A1 (de) 2014-09-10
CN104321300A (zh) 2015-01-28

Similar Documents

Publication Publication Date Title
IN2014CN03111A (de)
AU2018260825A1 (en) Compositions and Methods for Lowering Levels of High-Sensitivity (hs-CRP) in a Subject
BRPI0909040B8 (pt) derivados de azetidina e ciclobutano, seus usos, e composição
WO2014085830A3 (en) Screening assays for therapeutics for parkinson's disease
UA109459C2 (xx) ПОХІДНІ 5,6-ДИГІДРОІМІДАЗО[1,2-a]ПІРАЗИН-8-ІЛАМІНУ, ПРИДАТНІ ЯК ІНГІБІТОРИ БЕТА-СЕКРЕТАЗИ (BACE)
MX2011008448A (es) Uso de ester etilico del acido eisosapentaenoico para tratar hipertrigliceridemia.
TR201909777T4 (tr) Sübsti̇tüe ki̇nazoli̇nonlara yöneli̇k oral çabuk salimli formülasyonlar
AR084433A1 (es) Inhibidores de la faah y composiciones farmaceuticas que los contienen
EP4342546A3 (de) Verfahren zur verringerung des risikos von herz-kreislauf-ereignissen bei einem patienten in einer statintherapie
BR112014021634A8 (pt) inibidores de serina/treonina quinase,composições que os compreendem, seus usos e seus processos de preparação, e método de inibir a atividade da proteína quinase erk em uma célula
SG184222A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
HK1136283A1 (en) Compounds for the prevention and treatment of cardiovascular diseases
PH12013502369A1 (en) Diazacarbazoles and methods of use
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
UA104869C2 (uk) Фармацевтичні композиції, що містять ліганди рецептора дофаміну
UY32682A (es) "derivados de 1h-imidazo-[4,5-c]-quinolinona"
UY32691A (es) Compuestos de 1h-imidazo-[4,5-c]-quinolinona
GT201200252A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
MX2012006822A (es) 1,7-diazacarbazoles y metodos de uso.
IN2012DN05186A (de)
EP2257161A4 (de) Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie
IN2014CN03854A (de)
SV2009003286A (es) Sal de potasio cristalina de analogos de lipoxina a4
BR112013026680A2 (pt) composto, método de tratamento de uma doença inflamatória e composição farmacêutica
MY182553A (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions